EPC Contracting for Ophthalmic Plant – Algeria (2025–Ongoing)

In 2025, Grup Adel initiated a €6 million project for the construction of a modern ophthalmic pharmaceutical production plant in Algeria. Our scope of work includes full EPC contracting, the transfer of advanced sterile ophthalmic manufacturing technology, and the supply of all key equipment from reputable World manufacturers.

This project marks a significant milestone in our expanding pharmaceutical portfolio and demonstrates our commitment to delivering tailored, high-quality solutions for evolving regional healthcare needs.

Project Scope and Deliverables:

The ophthalmic plant project is being executed as a full turnkey solution. Grup Adel is responsible for managing the transfer of sterile ophthalmic manufacturing processes from a leading European technology partner to ensure the facility meets all international quality and regulatory benchmarks.

Key deliverables include:

• Customized basic and detailed engineering, adapted to Algeria’s local infrastructure and regulatory standards

• Procurement and delivery of essential machinery for formulation, aseptic filling, and packaging

• Supervised installation and commissioning of the production line, including hands-on training for operational teams

• Full compliance with GMP requirements, enabling safe and sterile manufacturing from day one

The selected equipment guarantees long-term operational efficiency, sterility assurance, and scalability for future production needs.

Strategic Importance:

This plant represents a major step in Algeria’s drive to localize pharmaceutical production and reduce reliance on imported medications—especially in high-value segments like ophthalmology. The project directly supports national goals of improving access to essential care while building industrial self-reliance.

Additionally, it enhances domestic technical capacity through structured knowledge transfer and workforce development initiatives supported by Grup Adel and its partners.

Looking Ahead:

As the project moves forward, Grup Adel remains focused on delivering lasting value and future-ready capabilities. The facility has been designed for future scalability, including potential expansions into preservative-free multi-dose systems and ophthalmic ointments.

Our forward-looking approach includes:

• Supporting the client in obtaining GMP certification in line with EMA and WHO guidelines

• Integrating smart manufacturing systems for real-time monitoring and digital optimization

• Providing long-term workforce development through structured training and local capacity building

• Exploring strategic partnerships to expand access to ophthalmic products within Algeria and across the region

This project reinforces Grup Adel’s role as a trusted provider of advanced pharmaceutical solutions, committed to delivering excellence, sustainability, and impact in every market we serve.